|
|
Post by BD on Jun 12, 2014 15:52:57 GMT -5
16:07 EDT MNKD theflyonthewall.com: MannKind initiated with an Outperform at RBC Capital
Target $16. :theflyonthewall.com
[We may be seeing a lot of these, so rather than starting a new thread for each new analyst comment, let's use this thread just for upgrades/downgrades/etc. so they can all be viewed in chronological order...
-BD]
|
|
|
|
Post by mannmade on Jun 13, 2014 9:06:54 GMT -5
HomeMailNewsSportsFinanceWeatherGamesGroupsAnswersScreenFlickrMobileMore
Yahoo Finance
Yahoo Finance
Search FinanceSearch Web
Sign In
Mail
Finance Home
My Portfolio
Market Data
Business & Finance
Personal Finance
Yahoo Originals
CNBC
Search for share pricesSearch for share prices
Report an IssueFri, Jun 13, 2014, 10:04AM EDT - U.S. Markets close in 5 hrs 56 mins
Dow Down0.05% Nasdaq Down0.17%
Upgrades & Downgrades History
UPGRADES & DOWNGRADES HISTORY
Date Research Firm Action From To
15-May-13 MLV & Co Initiated Buy
3-Dec-12 Brinson Patrick Initiated Market Outperform
13-Apr-12 Cowen & Co Initiated Neutral
12-Aug-11 JMP Securities Upgrade Mkt Perform Mkt Outperform
20-Jan-11 JMP Securities Downgrade Mkt Outperform Mkt Perform
20-Jan-11 Rodman & Renshaw Downgrade Mkt Outperform Mkt Perform
19-Oct-10 JMP Securities Initiated Mkt Outperform
25-Sep-09 Oppenheimer Downgrade Perform Underperform
4-Jun-09 Rodman & Renshaw Initiated Mkt Outperform
18-Dec-08 Oppenheimer Initiated Perform
7-Oct-08 Rodman & Renshaw Initiated Mkt Outperform
10-Apr-08 Piper Jaffray Downgrade Buy Neutral
9-Apr-08 Leerink Swann Downgrade Outperform Mkt Perform
10-Mar-08 Jefferies & Co Downgrade Buy Underperform
15-Jan-08 Robert W. Baird Initiated Neutral
9-Nov-07 JP Morgan Downgrade Overweight Neutral
6-Aug-07 Oppenheimer Downgrade Buy Neutral
14-Jun-07 Banc of America Sec Initiated Buy
8-Mar-07 Jefferies & Co Upgrade Hold Buy
4-Jan-07 JP Morgan Initiated Overweight
3-Nov-06 UBS Upgrade Neutral Buy
17-Aug-06 CIBC Wrld Mkts Initiated Sector Perform
21-Jul-06 Miller Johnson Initiated Market Perform
19-Jan-06 WR Hambrecht Upgrade Sell Hold
18-Jan-06 Piper Jaffray Upgrade Market Perform Outperform
22-Dec-05 Oppenheimer Initiated Buy
13-Oct-05 Leerink Swann Initiated Outperform
9-Sep-05 Jefferies & Co Upgrade Underperform Hold
11-Jul-05 Jefferies & Co Downgrade Hold Underperform
30-Jun-05 MDB Capital Group Initiated Sell
15-Jun-05 UBS Downgrade Neutral Reduce
13-Jun-05 Piper Jaffray Downgrade Outperform Market Perform
12-May-05 WR Hambrecht Initiated Sell
10-Feb-05 Wachovia Upgrade Mkt Perform Outperform
9-Nov-04 Jefferies & Co Initiated Hold
5-Oct-04 Advest Initiated Sell
1-Oct-04 Wachovia Downgrade Outperform Mkt Perform
13-Sep-04 Wachovia Initiated Outperform
10-Sep-04 Piper Jaffray Initiated Outperform
Add to Portfolio Add to Portfolio Set Alert Set Alert Email Email
Get Upgrades and Downgrades for Another Symbol: Symbol Lookup
Data provided by Briefing.com - Take a Free Trial
Complete Live market analysis of the U.S. stock and bond markets, technology stocks, economic releases, earnings reports, and day trading highlights.
|
|
|
|
Post by kc on Jun 13, 2014 9:55:57 GMT -5
Does anybody have a copy of the written RBC report. I guess that you have to be a RBC customer to obtain?
|
|
|
|
Post by mnkdfan on Jun 16, 2014 17:38:35 GMT -5
|
|
|
|
Post by otherottawaguy on Jun 30, 2014 10:19:53 GMT -5
GRIFFIN
SECURITIES
Member FINRA, SIPC
Keith A. Markey, Ph.D., M.B.A. June 30th, 2014
griffin.bluematrix.com/sellside/EmailDocViewer?encrypt=409e2cbd-0a15-4df1-bd66-2b1d3b72ba12&co=griffin&mime=pdf&id=replaceme@bluematrix.com
"maintaining our BUY rating on MNKD shares and have raised our price target to $15."
MannKind Corp. BUY
Target Price Change : Pharmaceuticals
A Giant Leap for Mannkind
FDA approves Afrezza for type 1 and type 2 diabetes. The label is less than might have been hoped for, though it came with no major issues. The inhalable insulin is not recommended for individuals who smoke or as a treatment of diabetic ketoacidosis. And, the label includes a boxed warning against the use of Afrezza for diabetics with asthma, chronic obstructive pulmonary disease, or lung cancer. In addition, physicians are advised to test each patient’s pulmonary function prior to prescribing the drug and every six months during the first year and subsequently on an annual basis. What is missing is the Company’s preferred language of “ultra-rapid acting insulin” or an acknowledgement of the fewer hypoglycemic events associated with Afrezza.
MNKD share price surged on the news. For reasons unknown, the stock had sold off by as much as 26% from the high of the day shortly before the FDA issued its decision. However, in the 30 minutes or so between the announcement and the close of normal trading for the day, the share price rebounded to close off only 5.5%. And in after-hours trading, the price continued to rise, surpassing $11 per share.
New clinical trials will be conducted. The FDA has requested three trials in its approval letter. One will be a 5-year study to assess the risk of lung cancer and another will establish the drug’s pharmacokinetic (PK) profile, safety and efficacy in children as young as four years old. Normally, young children are not involved in post-marketing studies right after a drug has been tested only in adults. Hence, the request suggests the FDA thinks the drug will be widely used by pediatric patients and it must be fairly comfortable with the drug’s safety profile. The third study will expand the data on Afrezza’s PK and pharmacodynamic profiles and on intra-patient variability.
Securing a marketing partner now tops the priority list. MannKind is seeking a partner(s) to support Afrezza in global markets. The goal is to have a partner for the United States to launch Afrezza by early 2015. MannKind initially estimated that a deal could come within 6 to 8 weeks after approval.
Afrezza will likely garner a sizable share of the diabetes market, as we describe in this report. Accordingly, we are maintaining our BUY rating on MNKD shares and have raised our price target to $15.
|
|
|
|
Post by otherottawaguy on Jun 30, 2014 10:32:15 GMT -5
Brinson Patrick
MannKind price target raised to $15 from $12 at Brinson Patrick
Brinson Patrick raised its price target for MannKind shares to $15 citing the FDA Approval of Afrezza for diabetes. The firm says the labeling, REMS program, and post-marketing requirements exceeded its expectations. It keeps an Outperform rating on the stock. |
|
|
|
Post by otherottawaguy on Jun 30, 2014 10:33:59 GMT -5
Just so I don't look like I am biased in my collecting:
JPMorgan maintaining a $6 price target
MannKind gaps up at open, but trades off earlier highs
The shares are up 7.6% at time of writing to $10.76 following an extremely volatile session late Friday afternoon eastern time. At current price resistance is at $10.99 and then at $11.22. Support is at $10.42. JPMorgan remains cautious on the stock, maintaining a $6 price target. |
|
|
|
Post by otherottawaguy on Jun 30, 2014 10:37:49 GMT -5
RBC Capital Outperform, 16.00 Target
MannKind Afrezza label largely as expected, says RBC Capital
After the FDA approved Mannkind's Afrezza, RBC Capital thinks most of the label, including warnings against use in COPD, etc., and for lung function testing, are as expected. The firm believes that the company's ability to find a marketing partner for the drug will be a key factor in determining its potential. The firm expects the company to find a partner and it keeps an Outperform rating on the shares |
|
|
|
Post by BD on Jun 30, 2014 12:01:55 GMT -5
We have this thread for analyst comments (including upgrades/downgrades), so I moved everything relevant from the other thread into this one.
|
|
|
|
Post by BD on Jul 1, 2014 6:45:35 GMT -5
06:32 EDT MNKD theflyonthewall.com: MannKind downgraded to Hold from Buy at MLV & Co. :theflyonthewall
Boo hiss...
|
|
|
|
Post by brentie on Jul 1, 2014 8:06:44 GMT -5
|
|
|
|
Post by BD on Jul 1, 2014 8:13:56 GMT -5
brentie, now our avatars are clearly displaying the approprate reaction...
|
|
|
|
Post by vissertrades on Jul 17, 2014 7:43:39 GMT -5
Found this on YMB...
Mannkind Corporation: Why Afrezza Would Completely Dominate The Insulin Market
July 16, 2014 | About: MNKD +0%
Decrease Font Size Increase Font Size PrintPrint EmailEmail
hvt2107
hvt2107
Articles (2) feed
Author's Website
3 followers
Follow
Mannkind Corporation (NASDAQ: MNKD) is a small company based in Valencia, California, focusing on the development and commercialization of medicine to treat diabetes. Mannkind's lead drug, Afrezza, was FDA approved on June 27, 2014, as treatment indication for patients with both Type 1 and Type 2 diabetes. The company's proprietary Technosphere is a novel drug delivery system that enabled Afrezza, super rapid acting insulin, to be delivered through a small whistle like device called the Dreamboat immediately prior to mealtime.
Description: Macintosh HD:Users:hungvinhtran:Desktop:cricket.png
Source: Mannkind
Unlike Mr. Market, who had been consistently wrong regarding Afrezza's advisory committee (ADCOM) votes, trials data, and the FDA final approval, I am highly optimistic regarding the drug's commercial success. Moreover, I hope to elucidate and clarify Afrezza superiority over needles injection through the lenses of a physician, patient advocates, researcher, and research analyst.
Despite needles being ultra thin these days, problems associated with prolonged use like inconvenience, scarring, stigma, and psychological fear persist. To self-administered injection, patients usually have to be excused to the bathroom. This does not bode well in modern society, one that is evolving toward increasing technological advancement. As a rule-of-thumb, a successful products necessitates user's friendliness and convenience.
In contrast to injections, Afrezza was ingeniously designed with unparalleled simplicity and convenience. By simply inhaling Afrezza through a tiny inconspicuous Dreamboat, patients could easily have insulin immediately available before mealtime to optimize blood sugar control. Diabetes would be easily as long as blood sugar is well controlled.
It is important to note that tissue scarring indeed occur with prolonged needle-use due to the needle breaking up collagen in subcutaneous tissue, and our body natural tendency to reestablish the tissue's integrity. Also, many patients who just started injection tend to make injecting mistakes that amplify scarring. The needle's aesthetic unappealing hinders patient's compliance, thus, explaining such high rates of diabetes complications.
Though pain associated with injections is real, the psychological anticipation of pain is more painful. This anticipation of pain persists, even if we could develop needles thinner than our hair that are technically "painless." Hence, patients who have not been on insulin injection, commonly referred to as "insulin-naïve" by physicians, would favor Afrezza over conventional insulin injections.
It is imperative for investors to note, needles stigma is real. When using needles in public for insulin injection, patients would fear being labeled as "junkies" and other colorful names. This social pressure has particularly strong impacts on patients with Type 1 diabetes, who tend to be teenage patients. Stigma is a powerful deterrence, hindering patient's compliance, and causing patients to lose their sight, limbs, kidneys, as well as, increasing the risks of heart diseases and hampering the body natural ability to heal itself.
In my prior work as an MD, I witnessed diabetes complications and its devastation not only to the patients but also to their family. Diabetes complications also have consequential economic ramifications as the annual spending tallied up to $245 billion. Hence, it would be reasonable for politicians, clinicians, and advocates to support Afrezza from the economic viewpoint.
Pertaining to the medical and scientific perspectives, conventional rapid acting insulin like Humolog and Novolog do not exhibit the same kinetics as Afrezza. The competitive edge for Afrezza is its super rapid acting pharmacokinetics, enabling it to mimic the action of the natural human pancreas. Hence, this clearly distinguished Afrezza from all competitors ... even the commonly mentioned inhale insulin, Exubera, which is delivered through a bong, because Exubera only exhibits regular RAA kinetics. Furthermore, Afrezza super rapid acting property would enable the drug to work faster, allowing patients to use insulin immediately prior to mealtime, having insulin exiting the body quicker, thus, minimizing the dreaded complication of hypoglycemia.
Nonetheless, Afrezza comes with the price exhibiting slightly less A1c – a marker of how well diabetes is controlled – reductions but it's insignificant when assessing the big picture. Prescribers like doctors, NP, or PA could always increase the prescribing dose of the basal insulin, as Lantus or Levemir, to achieve optimal hemoglobin A1c while enjoying the freedom from hypoglycemia, stigmatization, inconvenience, and tissue scarring.
My informal surveying of physician colleagues and patients indicated that the medical community would highly welcome Afrezza market entry. For instance, patients from "Better Health," which is a nonprofit diabetes support group, were fascinated with the story on Afrezza.
Regarding physicians prescribing pattern, personal preferences and more importantly patient's preferences indeed play significant roles. After all, a medically effective treatment would be obsolete if it does not win the patient's heart. It appeared that the overwhelming majority of patients highly favored Afrezza, forecasting the revolutionary drug's path toward being a blockbuster. Furtheremore, an independent research firm conducted surveys of physicians last year, also, revealed evidence of overwhelming physicians' support for Afrezza.
The bottom line is that Afrezza demonstrates characteristics of a potential blockbuster in the making, but Mr. Market is quoting Mannkind shares in the mid $9, which is highly undervalued versus comparative market analysis valuation of $38 per share. As Afrezza hit the market with increasing success, echoing stories from Main Street physicians and patients, Wall Street will quote the stock at significant premium than its current shares price. According to the Illustrious Investor Peter Lynch, it pays to bet against the pessimistic Mr. Market, as well as, to practice due diligence, patience, and conviction.
Readers could access 360 Biotech research articles on Mannkind by clicking on the referenced links below:
A Featured Presentation On Mannkind Corporation's Revolutionary Diabetes Treatment
Transcending Traditional Security Analysis, Integrated Investing Research Shed Light On Mannkind Corporation True Value
In Al We Trust
Amidst Buyout And Partnership Anticipation - Mannkind Is In Good Hands
Where's Mannkind Heading After The Historical Event Of Afrezza FDA Approval
FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation's Investigational Drug to Treat Diabetes
Mannkind Shareholders Focus On These Facts Rather Than Weekend Worrying
Why Rising Obesity Means Blockbuster Revenue For Afrezza
Mannkind Corporation: Catalyzing The Next Revolution In Diabetes Treatment
Mannkind Corporation: The Potential Revolutionary Treatment For Diabetes Delivering Value For Shareholders
Integrated Investing Research: Doctor Tran’s Top Quarterly
About the author:
hvt2107
I have the background as an MD and a researcher. I am currently the Chief Medical Analyst for Retail Investor 360 and I host my internet show 360 Biotech With Doctor Tran. I am also a contributing author for Seeking Alpha.
Visit hvt2107's Website
|
|
|
|
Post by BD on Jul 17, 2014 8:46:23 GMT -5
|
|
